To define low-, middle- and high-risk recurrence patients, apart from traditional clinical parameters such as tumor number, size, tumor stage, grade and whether it is carcinoma in situ, the immunohistochemical marker Ki-67 can also be used as an effective tool (25, 26). Here, MKI67 is linked to neoplasm.